ION440
ION440-CS1
Phase 2 small_molecule active
Quick answer
ION440 for Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome is a Phase 2 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IONIS PHARMACEUTICALS INC
- Indication
- Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active